Autolus Therapeutics Wins FDA Approval for AUCATZYL®

Autolus Therapeutics ( (AUTL) ) has provided an announcement.

Autolus Therapeutics has achieved a pivotal milestone with the FDA’s approval of AUCATZYL® for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This innovative CAR T therapy, showcasing significant efficacy and manageable safety, marks a breakthrough without the need for a Risk Evaluation and Mitigation Strategy (REMS). The approval is based on the promising results from the FELIX clinical trial, offering new hope for patients facing this aggressive cancer and setting the stage for broader availability in the U.S.

See more data about AUTL stock on TipRanks’ Stock Analysis page.